TY - JOUR
AR - COR-2018-2-105
TI - West Virginia Resident is First American to Receive Dicycloplatin Chemotherapy: A WVU Urologic Oncology Case Report
AU - Chad , Morley
AU - Chad, Crigger
AU - Jing Jie, Yu
AU - Mohamad , Salkini
AU - Shunchang , Jiao
JO - Clinical Oncology and Research
PY - 2018
DA - Mon 16, Jul 2018
SN - 2613-4942
DO - http://dx.doi.org/10.31487/j.COR.2018.02.005
UR - https://www.sciencerepository.org/west-virginia-resident-is-first-american-to-receive-dicycloplatin-chemotherapy-a-WVU-urologic-oncology-case-report_COR-2-105 
KW - Platinum Chemotherapy, Dicycloplatin, Tolerable Side Effects Bladder Cancer
AB - A 65-year-old Caucasian male presented with increasing hematuria over four months in 2016. Work up and
scans revealed a 1.5 cm bladder mass, with a subsequent pathologic diagnosis of non-invasive high-grade
papillary urothelial carcinoma. The patient declined BCG Immunotherapy and traveled to China soon after
diagnosis and transurethral resection for Dicycloplatin (DCP) chemotherapy. DCP is approved by the
Chinese FDA but only available at present in military hospitals. It is similar in molecular structure to
platinum-based chemotherapy drugs used in the West, its side effects reported to be more tolerable. The
patient received 8 weeks of IV DCP chemotherapy – he only experienced mild nausea, myralgia, a relative
leukopenia and thrombocytopenia (though within normal limits) and, importantly, no alopecia – then
returned to WV for quarterly surveillance. No recurrence of tumor has been observed to date; the most
recent cystoscopy was on April 24, 2018, 22 months after diagnosis and resection.